Carolina News reports that rising GLP-1 use across the country is pushing snack brands to rethink their pitch to shoppers. A student reporter looks at what is shifting.
Recap by typeshit. Post by @usccarolinanews on Instagram.
The Darling Ingredients unit says the supplement ingredient concentrates over ten neurosupportive peptides, with clinical trials planned to start in December.
The plastic surgeon weighs in on semaglutide and other GLP-1 drugs as more patients of every age turn to them for major weight loss.
Toby notes Lilly posted $22.97 billion in Q2 2026 revenue, up 46% in a year, driven by one molecule sold under two brand names.
Traders Union looks at whether Novo Nordisk shares can hold their gains, pointing to the Wegovy pill approval and recent trial data.
An FDA advisory panel voted to loosen restrictions on some experimental peptides, and Gladstone Institutes president Deepak Srivastava is warning about it.
Increased appetite topped the symptoms users linked to unapproved retatrutide, unlike trial data. Researchers stress the reports can't prove the drug caused anything.
Loading…